NCT06550232View on ClinicalTrials.gov

IV PAPAVERINE Prior to Propess for Labor Induction

PHASE4CompletedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

August 12, 2024

Primary Completion Date

March 23, 2025

Study Completion Date

March 23, 2025

Conditions
Induced Vaginal Delivery
Interventions
DRUG

Papaverine

Within 30-minutes prior to catheter insertion, women in the intervention group will receive IV-papaverine 80 mg in 100 ml 0.9% saline

OTHER

placebo

I.V Sallne

Trial Locations (1)

Unknown

Galilee Medical Center, Nahariya

All Listed Sponsors
lead

Western Galilee Hospital-Nahariya

OTHER_GOV

NCT06550232 - IV PAPAVERINE Prior to Propess for Labor Induction | Biotech Hunter | Biotech Hunter